WebDec 3, 2024 · The industry-funded and analyzed 2003 Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Added (CHARM-Added) trial … WebDec 3, 2024 · CHARM-Added. McMurray JJ, et al. "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added …
Heart failure with mid-range ejection fraction in CHARM ...
WebMethods and results: In 7598 patients enrolled in the CHARM Programme (HF across the spectrum of EF), we assessed characteristics, outcomes and treatment effect of … WebJan 1, 2003 · CHARM consists of three independent, parallel, placebo-controlled studies in patients with symptomatic HF. In the CHARM Preserved component trial, patients with … splint compact traction
Candesartan in Heart Failure—assessment of reduction in …
WebCHARM-Alternative and CHARM-Added trials. The CHARM-Added trial required patients to take an ACE inhibitor. If investiga-tors observed that an ACE inhibitor was not … WebThe CHARM-Added and CHARM-Alternative trial data were pooled with outcome analysis for the present study based on the intention-to-treat principle in all randomized patients. All major outcomes were analyzed by time to first event. For the primary analysis a log-rank test stratified by trial was employed to compare the time-to-event distributions. WebJan 1, 2003 · Principal Findings: The most frequently reported reason for ACE inhibitor intolerance was cough (70% in the candesartan arm and 74% in the placebo arm). The primary endpoint of cardiovascular (CV) mortality or chronic heart failure (CHF) hospitalization was lower in the candesartan arm compared with placebo (33.0% vs. … splint coaptation